KEYMED BIOSCIENCES -0001 Cash Flow-to-Debt Ratio
KEYMED BIOSCIENCES -0001 cash flow-to-debt ratio. KEYMED BIOSCIENCES -0001 (64Z) has a Cash Flow-to-Debt Ratio of -0.49x as of December 2025, meaning its operating cash flow of €-712.41 Million could theoretically repay 0% of its total liabilities (€1.44 Billion) in one year. See KEYMED BIOSCIENCES -0001 free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of KEYMED BIOSCIENCES -0001 (2021–2025)
Cash flow-to-debt ratio of KEYMED BIOSCIENCES -0001 from 2021 to 2025. Historical debt coverage capacity for KEYMED BIOSCIENCES -0001 across 5 annual periods. Also explore 64Z net asset momentum to track the company's year-over-year net asset growth rate.
KEYMED BIOSCIENCES -0001 Cash Flow-to-Debt Ratio by Year (2021–2025)
KEYMED BIOSCIENCES -0001 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for KEYMED BIOSCIENCES -0001. For the full cash flow conversion analysis, see 64Z cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.49x | €-712.41 Million | €1.44 Billion | ▲ +19.2% |
| 2024 | -0.61x | €-789.63 Million | €1.29 Billion | ▼ -80.5% |
| 2023 | -0.34x | €-303.62 Million | €896.11 Million | ▲ +50.0% |
| 2022 | -0.68x | €-401.93 Million | €593.10 Million | ▲ +8.7% |
| 2021 | -0.74x | €-214.64 Million | €289.07 Million | — |